Speaker
Description
Neurodegenerative diseases impose a significant burden on society, leading to substantial healthcare costs and profoundly impacting the quality of life for patients and their families. In a search for innovative treatments, translational research plays a significant role by bridging basic discoveries to clinical applications for conditions like Alzheimer’s and Parkinson’s. Nevertheless, this type of research poses ethical questions about responsibilities of preclinical researchers in the process of translation.
The aim of this study was to map the ethical risks in the process of translation of preclinical research results to clinical application in the context of development of innovative treatments for neurodegenerative diseases from the point of view of researchers. We performed four focus group discussions with researchers in 2024, one session took place in person in Finland, while the other three were held online via Zoom, engaging participants from the Netherlands, Canada, Latvia, and Estonia.
| Presenting author | Signe Mežinska |
|---|
